Filing Flows › Scribe Therapeutics (SCTX) › Stock forecast & fair value
Scribe Therapeutics (SCTX) stock forecast and price target
Scribe Therapeutics (SCTX) trades at $15.70. 4 analysts' median price target is $59.00 (+276%), from $50.00 to $60.00.
Scribe Therapeutics' latest quarter
Scribe Therapeutics, Q2 2026: revenue $1.9M (-61% year over year), operating margin -489.8%, net loss $6.5M. The chart follows the revenue to costs, profit and cash.
Questions
What is the price target for SCTX stock?
The median of 4 analysts' 12-month targets is $59.00, +276% from $15.70; the range is $50.00 to $60.00. The average rating is none.
Does Scribe Therapeutics usually beat earnings estimates?
It beat the consensus EPS estimate in 100% of the quarters on record.
Is SCTX stock a buy?
Filing Flows does not give advice. It shows what analysts expect, what each valuation method implies and the figures behind them, read from SEC filings, so you can judge for yourself.
Updated Nov 8, 2026. Read automatically from SEC filings and public data; errors are possible. Not investment advice.